Jagsonpal Pharma
NSE: JAGSNPHARM · Pharmaceuticals
Snapshot
Unlock Jagsonpal Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jagsonpal Pharmaceuticals Limited is an Indian pharmaceutical company focused on the development and manufacturing of bulk drugs and formulations. Its product portfolio spans women's health, pain management, analgesics, and a diverse range of general medicines.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical products in various dosage forms, including tablets, capsules, and syrups. It operates as a subsidiary of Aresko Progressive Private Limited, targeting therapeutic segments such as ENT, dentistry, and pregnancy care.
- Founded:1964
Growth Outlook
Growth is expected to be driven by the company's established presence in niche therapeutic areas like women's healthcare and pain management. Continued focus on its existing product range in the Indian market remains a primary strategic objective.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and manufacturing standards that, if not met, could lead to product recalls or operational shutdowns.
- Price Controls. Government-mandated price caps on essential medicines in India may limit the company's ability to adjust pricing to offset rising input costs.
- Competitive Intensity. The company faces significant competition from both large multinational corporations and domestic generic manufacturers, which may pressure profit margins.
- Supply Chain Volatility. Dependence on the availability and pricing of raw materials and active pharmaceutical ingredients (APIs) poses a risk to consistent production cycles.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Jagsonpal Pharma and 5,000+ companies — free.
Key Metrics
REVENUE
₹287 Cr
TTM · standalone
NET PROFIT
₹43 Cr
TTM · standalone
EPS
₹6.40
TTM · standalone
RETURN ON EQUITY
17.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
22.4%
TTM · standalone
P/E
35.4x
Q4 FY26 · standalone
EV/EBITDA
21.2x
Q4 FY26 · standalone
EBITDA MARGIN
24.4%
TTM · standalone
NET PROFIT MARGIN
13.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Jagsonpal PharmaJAGSNPHARM | 1,216 | 35.45 | 21.17 | 6.9% | 24.4% | 17.3% | 22.4% | -7.9% |
Lincoln Pharma.LINCOLN | 1,173 | 13.71 | 9.06 | 7.7% | 19.5% | 12.7% | 16.4% | +7.8% |
Ind-Swift Labs.INDSWFTLAB | 1,168 | 44.47 | 17.62 | 226.0% | 14.7% | 3.4% | 4.0% | +121.7% |
Venus RemediesVENUSREM | 1,157 | 23.25 | 14.80 | 18.0% | 20.9% | 17.5% | 22.1% | +239.7% |
Hester BiosHESTERBIO | 1,150 | 36.08 | 23.45 | 6.9% | 29.0% | 17.6% | 15.2% | +31.0% |
Sakar HealthcareSAKAR | 1,148 | 65.52 | 28.44 | 41.8% | 28.3% | 10.3% | 13.3% | +148.6% |
As of Q4 FY26
Financials
Jagsonpal Pharma
NSE: JAGSNPHARM · Pharmaceuticals
Snapshot
Unlock Jagsonpal Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jagsonpal Pharmaceuticals Limited is an Indian pharmaceutical company focused on the development and manufacturing of bulk drugs and formulations. Its product portfolio spans women's health, pain management, analgesics, and a diverse range of general medicines.
Business Model
The company generates revenue through the manufacturing and sale of pharmaceutical products in various dosage forms, including tablets, capsules, and syrups. It operates as a subsidiary of Aresko Progressive Private Limited, targeting therapeutic segments such as ENT, dentistry, and pregnancy care.
- Founded:1964
Growth Outlook
Growth is expected to be driven by the company's established presence in niche therapeutic areas like women's healthcare and pain management. Continued focus on its existing product range in the Indian market remains a primary strategic objective.
Key Risks
- Regulatory Compliance. The pharmaceutical industry is subject to stringent quality and manufacturing standards that, if not met, could lead to product recalls or operational shutdowns.
- Price Controls. Government-mandated price caps on essential medicines in India may limit the company's ability to adjust pricing to offset rising input costs.
- Competitive Intensity. The company faces significant competition from both large multinational corporations and domestic generic manufacturers, which may pressure profit margins.
- Supply Chain Volatility. Dependence on the availability and pricing of raw materials and active pharmaceutical ingredients (APIs) poses a risk to consistent production cycles.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Jagsonpal Pharma and 5,000+ companies — free.
Key Metrics
REVENUE
₹287 Cr
TTM · standalone
NET PROFIT
₹43 Cr
TTM · standalone
EPS
₹6.40
TTM · standalone
RETURN ON EQUITY
17.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
22.4%
TTM · standalone
P/E
35.4x
Q4 FY26 · standalone
EV/EBITDA
21.2x
Q4 FY26 · standalone
EBITDA MARGIN
24.4%
TTM · standalone
NET PROFIT MARGIN
13.6%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26